FDA Approves New Radioligand Therapy and Diagnostic for mCRPC

The agency has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for treatment and gallium Ga 68 gozetotide (Locametz) as a diagnostic for use with PET imaging.

Related Keywords

New York ,United States ,California ,Memorial Sloan Kettering Cancer Center ,San Francisco ,Los Angeles ,Michaelj Morris ,Thomas Hope ,Oliver Sartor ,University Of California ,Drug Administration ,Tulane Cancer Center ,Advanced Accelerator Applications ,Medscape Medical ,Jeremie Calais ,Medscape Medical News ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Chemotherapy ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Neoplasm ,Positron Emission Tomography Pet ,Pet ,Positron Emission Tomography ,Tumor ,Biologic Therapy ,Immunotherapy ,